Abstract IA17: Synthetic-lethal strategies for MYC-driven cancers

MYC is an essential, pleiotropic transcription factor whose amplification or deregulated expression is one of the most commonly occurring events in cancer. Despite the importance of MYC as a therapeutic target, no available drugs directly inhibit MYC transcriptional activity. Our group has undertaken several orthogonal approaches to identify MYC-pathway directed synthetic-lethal interactions. Using cell-based and transgenic animal models we have identified new potential therapeutic targets. These include metabolic, cell cycle and novel kinase vulnerabilities of MYC-driven cancers that will be discussed.Citation Format: Andrei Goga. Synthetic-lethal strategies for MYC-driven cancers [abstract]. In: Proceedings of the AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; Jan 4-7, 2017; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2017;16(10 Suppl):Abstract nr IA17.
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Finding Synthetic Lethal Interactions through Functional Genomics: Oral Presentations - Invited Abstracts Source Type: research